ArticleInternational journal of medical informatics2025
Hypothesis: Net benefit as an objective function during development of machine learning algorithms for medical applications.
Article in International journal of medical informatics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Rethinking Risk Prediction in Preeclampsia: From Biomarkers to Mechanistic Phenotypes and Longitudinal Models.International journal of molecular sciences · 2026Review
- The continuous net benefit: assessing the clinical utility of prediction models when informing a continuum of decisions.Diagnostic and prognostic research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Net benefit is the most widely used metric for evaluating the clinical utility of medical prediction models. The approach applies decision analytic theory to weight true and false positives depending on the relative consequences of different decision outcomes. It is plausible that there are at least some machine learning scenarios where optimization of the objective function during model development will not optimize net benefit during model evaluation. We therefore hypothesize that optimizing net benefit during model development will in some cases ultimately lead to higher clinical utility than optimizing for mean square error or some other unweighted loss function. There is some preliminary evidence that this does indeed occur. We accordingly recommend further methodologic research to determine the use cases where net benefit should be the objective function during model development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.